High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control

Osteoporosis International

Volumn 25, Issue 5, 2014, Pages 1527-1533

  Neumann, T ^a   Lodes, S ^a   Kastner B ^a   Franke, S ^a   Kiehntopf, M ^a   Lehmann, T ^a   Muller U A ^a   Wolf, G ^a   Samann A ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Fractures; Pentosidine; Type 1 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ENDOGENOUS SECRETORY RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C; PENTOSIDINE; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ARGININE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN RECEPTOR; LYSINE;

ADULT; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FAMILY HISTORY; FEMALE; FEMUR NECK; FRACTURE; GLYCEMIC CONTROL; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PREMENOPAUSE; PRIORITY JOURNAL; SMOKING; SPINE FRACTURE; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RISK ASSESSMENT;

ADULT; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BONE DENSITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LYSINE; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; RECEPTORS, IMMUNOLOGIC; RISK ASSESSMENT;

EID: 84899648190     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2631-7     Document Type: Article

References (33)

1. Zhukouskaya VV, Eller-Vainicher C, Vadzianava VV, Shepelkevich AP, Zhurava IV, Korolenko GG, Salko OB, Cairoli E, Beck-Peccoz P, Chiodini I (2013) Prevalence of morphometric vertebral fractures in patients with type 1 diabetes. Diabetes Care 36:1635-1640
2. Nicodemus KK, Folsom AR (2001) Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197
3. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 18:427-444
4. Neumann T, Samann A, Lodes S et al (2011) Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with type 1 diabetes. Diabet Med 28:872-875
5. Danielson KK, Elliott ME, LeCaire T, Binkley N, Palta M (2009) Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int 20:923-933
6. Seeman E, Delmas PD (2006) Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
7. Busch M, Franke S, Ruster C, Wolf G (2010) Advanced glycation end-products and the kidney. Eur J Clin Invest 40:742-755
8. Miyata T, Wada Y, Cai Z, Lida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C (1997) Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51:1170-1181
9. Salman AG, Mansour DE, Swelem AH, Al-Zawahary WM, Radwan AA (2009) Pentosidine - a new biochemical marker in diabetic retinopathy. Ophthalmic Res 42:96-98
10. Dong XN, Qin A, Xu J, Wang X (2011) In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption. Bone 49:174-183
11. Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195-214
12. Vashishth D (2007) The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep 5:62-66
13. Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT (2007) Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40:345-353
14. Karim L, Tang SY, Sroga GE, Vashishth D (2013) Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos Int 24:2441-2447
15. Tanaka S, Kuroda T, Saito M, Shiraki M (2011) Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women. J Bone Miner Res 26:2778-2784
16. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T (2008) Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 93:1013-1019
17. Schwartz AV, Garnero P, Hillier TA et al (2009) Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 94:2380-2386
18. Kislinger T, Fu C, Huber B et al (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749
19. Yonekura H, Yamamoto Y, Sakurai S et al (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097-1109
20. Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T (2009) Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes care 32:2263-2268
21. Mackey DC, Lui LY, Cawthon PM, Bauer DC, Nevitt MC, Cauley JA, Hillier TA, Lewis CE, Barrett-Connor E, Cummings SR (2007) High-trauma fractures and low bone mineral density in older women and men. JAMA 298:2381-2388
22. Franke S, Muller A, Sommer M, Busch M, Kientsch-Engel R, Stein G (2003) Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol 59:88-97
23. Sun JK, Keenan HA, Cavallerano JD et al (2011) Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study. Diabetes Care 34:968-974
24. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP (2001) Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 28:195-201
25. Hein G, Weiss C, Lehmann G, Niwa T, Stein G, Franke S (2006) Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 65:101-104
26. Hein G, Wiegand R, Lehmann G, Stein G, Franke S (2003) Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford) 42:1242-1246
27. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P (2007) Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem 282:5691-5703
28. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22:3716-3727
29. Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y (2003) Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diabetes Complicat 17:16-21
30. Lapolla A, Reitano R, Baccarin L, Sartore G, Plebani M, Fedele D (2005) Pentosidine plasma levels and relation with metabolic control in diabetic patients. Horm Metab Res 37:252-256
31. Nyman JS, Even JL, Jo CH et al (2011) Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone. Bone 48:733-740
32. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2008) Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men. Calcif Tissue Int 83:324-331
33. Honkanen K, Honkanen R, Heikkinen L, Kroger H, Saarikoski S (1999) Validity of self-reports of fractures in perimenopausal women. Am J Epidemiol 150:511-516